nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-4A00FB19·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Physiology·Basis: Full text·Type: Observational study

Genetic drivers of progression in Alzheimer's disease are distinct from disease risk.

Cohen et al.Cohen, Fernandez, Yaman et al.·2026·Alzheimer's research & therapy·10.1186/s13195-026-02036-1 ↗

Primary claim

Established AD risk factors, including APOE‑ε4 dosage and polygenic risk scores, were not associated with disease progression in amyloid positive individuals who are actively declining.

Tentative · model-dependent APOE results and limited power prevent a firm null conclusion
In brief

Amyloid-confirmed longitudinal genetics offers useful progression hypotheses, but unresolved internal inconsistencies prevent firm conclusions about APOE and progression-specific biology.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Abstract

BACKGROUND: Recent trials in Alzheimer’s disease (AD) demonstrate encouraging outcomes. These trials target risk mechanisms identified through genetic analysis whilst directly aiming to reduce progression rates. Evidence from other neurodegenerative diseases suggests the genetics of progression is distinct from risk of disease. To expand these initial successes and improve clinical outcomes further we need to understand genetics of progression of disease. These can be deduced through rigorous analysis of meticulously phenotyped longitudinal cohorts. In this study we first looked at known genetic drivers of risk, namely polygenic risk scores for AD and APOE‑ε4, to assess their role in progression. This was then extended to a genome wide association analysis to identify the role of other genetic variants in progression of AD. METHODS: A total of 387 individuals with genetic data, amyloid positivity, and in active decline (ADNI (n = 222) and AIBL(n = 165)) were used to perform generalised mixed effects linear model genome wide association studies of longitudinal cognitive decline as measured by mini mental state examination (MMSE). The resulting summary statistics were subjected to functional annotation, and colocalisation analyses. RESULTS: Established AD risk factors, including APOE‑ε4 dosage and polygenic risk scores, were not associated with disease progression in amyloid positive individuals who are actively declining. A mixed effects GWAS meta-analysis revealed one genome-wide significant locus on chromosome 22 (rs78369883) and several nominally significant loci linked with AD progression. Functional annotation, finemapping, and colocalisation analyses implicated genes primarily involved in immune response, neurodegeneration (including tau pathology), brain resilience, and neurogenesis. These progression-related genes were significantly enriched in neuronal-interferon-microglial signalling pathways and normal homeostatic processes of neuronal networks, with specific enrichment in dopaminergic and inhibitory neuronal populations. CONCLUSION: These findings enhance our understanding of the biological underpinnings of AD progression, opening new avenues for therapeutic intervention.

Key Claims

Primary finding · Tentative

Established AD risk factors, including APOE‑ε4 dosage and polygenic risk scores, were not associated with disease progression in amyloid positive individuals who are actively declining.

model-dependent APOE results and limited power prevent a firm null conclusion

Abstract, Results; Results, APOE and Polygenic Risk Scores; Tables 2–3
Quote verified
Secondary · Supported

A mixed effects GWAS meta-analysis revealed one genome-wide significant locus on chromosome 22 (rs78369883) and several nominally significant loci linked with AD progression.

the reported associations are directly identified, though the small unreplicated discovery sample limits certainty

Abstract; Results, Meta-analysis; Table 4
Quote verified
Secondary · Tentative

These progression-related genes were significantly enriched in neuronal-interferon-microglial signalling pathways and normal homeostatic processes of neuronal networks, with specific enrichment in dopaminergic and inhibitory neuronal populations.

enrichment rests on genes mapped from nominal discovery loci without independent biological validation

Abstract; Results, Implicated Pathways; Figures 7–9
Quote verified
Secondary · Tentative

the genetic drivers of AD pathogenesis are, at least mostly, distinct from those modulating progression.

the comparison relies on underpowered nulls rather than a direct, replicated risk-versus-progression analysis

Discussion, Uncoupling Genetic Factors of AD Risk and Progression; Title
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Amyloid-confirmed longitudinal progression phenotype

Participants were selected using cohort-specific amyloid criteria and analysed through repeated MMSE measurements, focusing the study on decline after pathological confirmation.

↳ Methods, Patient Filtering; Figure 1

#methodological rigour

Broad longitudinal genetics analysis pipeline

The analysis combines random-intercept and random-slope models, cohort-specific GWAS meta-analysis, fine-mapping, colocalisation, and cell-type enrichment.

↳ Methods, Mixed-effects Modelling through Co-localisation Analysis

#positioning

Contrasting literature directly addressed

The Discussion compares its APOE and PRS findings with prior progression analyses and identifies amyloid restriction and baseline-stage adjustment as possible explanations for disagreement.

↳ Discussion, Uncoupling Genetic Factors of AD Risk and Progression

Limitations

#reporting

Headline APOE result remains contradictory

The Abstract reports no APOE association with progression, while the nonlinear model reports significantly improved fit and approximately 16% faster decline per ε4 allele. Table 2 also does not clearly display the stated APOE×time coefficient.

↳ Abstract; Results, APOE; Table 2; Figure 4

#methodological rigour

Reported statistics do not reconcile

Table 6 includes beta, standard-error, and p-value combinations that are arithmetically incompatible, while PRS counts and locus totals vary across methods, results, and tables.

↳ Methods, Polygenic Risk Scores; Results, Meta-analysis and Fine-mapping; Tables 3, 4, and 6

#positioning

Exploratory biology receives strong interpretation

Nominal, unreplicated loci support pathway and cell-type hypotheses, but the Discussion describes distinct neuronal drivers and validation across annotation datasets more firmly than the evidence permits.

↳ Results, Implicated Pathways; Discussion, Cell Types Implicated and Study Limitations

Does this match your read? Add your assessment ↓

Nabu Commentary

The amyloid-confirmed longitudinal design and mixed-effects framework provide a useful basis for studying progression rather than susceptibility. The main interpretation is weakened because the Abstract's APOE null conflicts with the significant nonlinear result in Figure 4, while Table 2 does not clearly show the reported interaction. The single genome-wide association and downstream pathway analyses are appropriately useful as hypotheses, but the small unreplicated sample and selection on active decline do not support firm mechanistic conclusions. The Discussion addresses prior studies and acknowledges major limitations, yet several concluding claims remain stronger than those limitations allow.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.8±0.2

Contribution
2.9

The amyloid-positive longitudinal progression design addresses a meaningful distinction from susceptibility GWAS. Its advance remains preliminary because the central risk-factor null is model-dependent and the discovery associations lack independent replication.

Abstract; Results, APOE and Meta-analysis; Discussion, Uncoupling Genetic Factors of AD Risk and Progression

Established AD risk factors, including APOE‑ε4 dosage and polygenic risk scores, were not associated with disease progression

Methodological Rigour
2.7

The study combines random-slope mixed models, cohort-specific GWAS meta-analysis, fine-mapping, and colocalisation. Methodological Rigour is constrained by selection on amyloid positivity and active decline, exploratory downstream thresholds, mechanistic overreach, and incompatible statistics in Table 6.

Methods, Patient Filtering and Mixed-effects Modelling; Results, Fine-mapping; Table 6
Reporting
2.9

The manuscript is structurally followable, but its headline APOE null does not communicate the significant nonlinear association reported later. Confusing Table 2 labelling and power-interval presentation further impede interpretation.

Abstract; Results, Power Analysis and APOE; Table 2; Figures 3–4

Each ε4 allele accelerated the decline rate by approximately 16%.

Positioning
2.8

The Discussion engages the closest contrasting progression studies and acknowledges limited power, cohort selection, and absent external validation. Positioning is capped because later claims of confident conclusions and biological validation are stronger than those limitations permit.

Discussion, Uncoupling Genetic Factors of AD Risk and Progression; Study Limitations and Future Direction; Cell Types Implicated

Nevertheless, several conclusions can be drawn with confidence.

Lower confidence on Methodological Rigour, Reporting — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkNoted
  • Established AD risk factors, including APOE‑ε4 dosage and polygenic risk scores, were not associated with disease progression in amyloid positive individuals who are actively declining: "Established AD risk factors, including APOE‑ε4 dosage and polygenic risk scores, were not associated with disease progression in amyloid positive individuals who are actively declining." (Abstract, Results) vs "The inclusion of APOE‑ε4 dosage as a predictor of the decline-rate parameter significantly improved model fit (likelihood ratio test p = 0.014), corresponding to an estimated ~ 16% acceleration in MMSE decline per ε4 allele." (Results, APOE). The unqualified absence-of-association claim is contradicted by the paper's nonlinear model, which reports an APOE-ε4 decline-rate association at p = 0.014 and approximately 16% acceleration per allele. → Not supported by the paper's own data
  • A mixed effects GWAS meta-analysis revealed one genome-wide significant locus on chromosome 22 (rs78369883) and several nominally significant loci linked with AD progression: "Table 4Summary statistics of meta-analysis independent signals at p < 5 × 10–05." (Table 4, caption) vs "22:26,417,956rs761670TC0.4550.0436.85 × 10–05MYO18B, SEZ6L, TFIP11" (Table 4, rs761670 row). Counting Table 4 gives 23 rows, of which rs761670 has p = 6.85 × 10–05 above the stated 5 × 10–05 cutoff, leaving one genome-wide significant row and 21 additional rows below that cutoff rather than 22 additional qualifying independent signals. → Conclusion holds
Reporting and transparencyNoted

Reporting gaps concern the APOE interaction label, power intervals at different sample sizes, PRS counts, fine-mapping statistic definitions, the colocalisation sample size, and an unnamed GitHub repository; these do not establish additional corrected results.

Conflict of interest: not stated · Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: declared

Reference IntegrityClean

105 references in manuscript 105 of 105 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSuggested
AdvanceAdvances
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The evidence is an observational genetic association study in two pooled cohorts, with the authors themselves noting the lack of an external validation cohort and need for replication.

From the paper
“Understanding these variants and pathways will provide targeted new opportunities for therapies around the time that MMSE scores start to decline”

The paper names possible real-world uses of its findings, namely new therapies and biomarker detection options, but does not specify who would act on them.

Pathway

Drug developers and clinical trial teams could target the progression-specific genes and pathways identified here to design therapies slowing cognitive decline in established Alzheimer's disease.

Barrier

The small sample of 387 amyloid-positive individuals, a single genome-wide significant locus, and no external replication leave the progression associations and implicated genes unvalidated.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's disease

    2026 · Neurology and psychiatry

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Divergent toxicity mechanisms of amyloid-beta aggregates arising from a single aggregation reaction

    2026 · Basic medicine

    Primary claim

    aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity

    Tentative
    Evidence Score
    2.8±0.2
    Reliability
    Caveats
  3. A timeline of tau-mediated synaptotoxicity

    2026 · Basic medicine

    Primary claim

    even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    No concerns

How the rubric works →